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BDCAFAbstract Behc¸et’s disease (BD) is a chronic multisystem disorder characterized by recurrent uve-
itis, oral aphthae, genital ulcers, and skin lesions. Evidence suggests an exaggerated response to
increased cytokine and chemokine production and function.
Aim of the work: To determine serum tumor necrosis factor-alpha (TNF-a) levels in BD and its
relation to clinical manifestations, disease activity and acute phase reactants.
Patients and methods: Thirty Egyptian male patients with BD (active n= 20, inactive n= 10)
and 20 age and sex matched healthy control subjects were included in this study. Serum TNF-a level
was determined and correlated with high sensitivity C-reactive protein (hs-CRP), erythrocyte
sedimentation rate (ESR) and Behc¸et’s disease current activity form (BDCAF).
Results: The TNF-a level of BD patients was signiﬁcantly higher (30.75 ± 16.94 pg/ml) com-
pared with the control group (5.08 ± 3.19 pg/ml; P< 0.0001). Patients with ocular manifestation
had a statistically signiﬁcant higher TNF-a than those without (P= 0.007). The TNF-a level was
signiﬁcantly higher in those with active disease (36.51 ± 16.36 pg/ml) compared to those inactive
(19.24 ± 11.78 pg/ml). However there was a statistically signiﬁcant difference in ESR and
Hs-CRP only between the active group and controls (P= 0.0001 and 0.001, respectively) and
not between active and inactive groups.
140 M. El Menyawi et al.Conclusion: High levels of TNF-a indicate the activation of immune response in BD. Serum
TNF-a seems to be related to disease activity. High levels of TNF-a were present in patients with
active ocular disease, raising the hope of the efﬁcacy of anti TNF-a agents in the treatment of
refractory ocular involvement.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Behc¸et’s disease (BD) is a multisystem inﬂammatory disorder,
currently classiﬁed as vasculitis. Its etiopathogenesis is unclear,
but environmental, genetic and autoimmune factors have been
considered [1]. The diagnosis of BD is based on clinical criteria
and no pathognomonic laboratory ﬁndings exist [2]. Proposed
exogenous triggers include both bacterial and viral infections,
which may then lead to dysregulation of the immune system,
ultimately leading to the phenotypic expression of disease [3].
Behc¸et’s disease can involve almost every organ and system
in the body and has extremely diverse manifestations [4].
Growing evidence indicates that oxidative stress is increased
in BD which causes tissue damage and is an essential event
in its etiopathogenesis [5].
Inﬂammation in BD is thought to be mediated by cytokines
derived from T-helper type 1 lymphocytes, including tumor
necrosis factor-alpha (TNFa) [6]. Tumor necrosis factor-alpha
(TNF-a) is a proinﬂammatory cytokine that plays a signiﬁcant
role in the immune response in BD [7].
Eye involvement in Behc¸et’s disease (BD) is frequent and an
important cause of morbidity. The mean age at onset of uveitis
is between 20 and 30 years in male patients. Ocular involve-
ment includes anterior, posterior or panuveitis. Uveitis may
be the presenting manifestation of the disease in 20% of cases
or may appear 2 or 3 years after the disease onset. The esti-
mated risk of blindness at 5 years ranges from 15% to 25%
[8]. Increased levels of circulating TNF and soluble TNF
receptors in the peripheral blood of patients with active dis-
ease, as well as high levels of TNF in the aqueous humor from
patients with BD associated uveitis have been reported [9]. The
treatment of BD is frequently associated with challenges, par-
ticularly in cases with eye involvement. Recurrent oral and
genital aphthous ulcerations are the hallmarks of BD but ocu-
lar disease is one of its main morbidities and considered to be
the most difﬁcult to manage [10]. The main goals in the man-
agement of patients with BD uveitis are the rapid control of
intraocular inﬂammation, the prevention of recurrent attacks,
the achievement of complete remission, and preservation of vi-
sion. The medical treatment of patients with severe uveitis re-
lies on the use of systemically administered drugs, including
corticosteroids and cytotoxic agents. Anti-TNF agents seem
to be efﬁcient and well-tolerated alternative therapeutic
options [8].
The members of the TNF family play critical roles as prom-
inent mediators of immune regulation and inﬂammatory
response [11]. It was reported that TNF-a related polymor-
phism could play an important role in the development of
BD [12].
The aim of the present work was to determine serum TNFa
levels in BD, and its relation to clinical manifestations, disease
activity and acute phase reactants.2. Patients and methods
Patients with Behc¸et’s disease (BD) fulﬁlling the international
study group criteria for the diagnosis of BD [2] were studied
during both clinically active (clinically active eye affection or
recent active vascular insult) or inactive stage. Clinical activity
was assessed at the time of venipuncture using Behc¸et’s Disease
Current Activity Form (BDCAF) [13]. Thirty Egyptian male
patients with BD (mean age 34.3 ± 9.9 years), age and
sex matched 20 healthy control subjects (mean age
33.05 ± 8.08 years) from a similar ethnic background were in-
cluded in this study. Subjects with any disorder as hepatic, re-
nal disease, diabetes or essential hypertension were excluded
from the study. All patients were subjected to full history tak-
ing, detailed history of drug use, clinical examination, pathergy
test and laboratory investigations including complete blood
count (CBC), erythrocyte sedimentation rate (ESR), highly
sensitive C-reactive protein (Hs-CRP) determined by enzyme
linked immune-sorbent assay (ELISA) and serum TNF-a. Ser-
um TNF-a measurement was done by using TNFa ELISA kits
provided by Avibion, Helsinki, Finland. Immediately after
blood sampling serum was obtained by centrifugation at
800g at 4 C for 15 min and stored at 70 C. The minimum
detectable dose of TNF-a is 1.7 pg/ml. Fundus examination
including slit lamp, and arterial or venous doppler when
indicated was performed. All patients were informed about
the procedure. The local ethics committee at Cairo University
Faculty of Medicine also approved this study.
Statistical Package of social science (SPSS) version 15.0 was
used for the analysis of data. Data were summarized as mean
andSD, percentage.T test was used for the analysis of twoquan-
titative data. One way ANOVA test was used for comparison of
more than 2 quantitative data followed by post Hoc test for
detection of signiﬁcance. Spearman correlation was also done.
rwas considered weak if<0.25, mild ifP0.25 -<0.5, moderate
if P0.5 - <0.75 and strong if P0.75. P-value was considered
signiﬁcant if <0.05*.
3. Results
At the time of our study, oral ulcers were present in 19 patients
(63.3%), 14 patients had genital ulcers (46.7%), 9 patients had
acnei-form skin lesions (30%), and 5 patients had erythema
nodosa (16.7%) (Table 1). The disease duration ranged from
1 month to 21 years with a mean of 59.8 ± 61.9 years.
In twelve patients (40%) ocular involvements were detected
(bilateral iridocyclitis, vitritis, retinal vasculitis, uveitis, or ret-
inal hemorrhage). Seventeen patients (56.7%) showed a posi-
tive pathergy test and 6 patients had active vascular affection
(20%); (3 patients had DVT, 2 patients had thrombophlebitis
and 1 patient had popliteal aneurysm) (Table 1). Twenty
patients were clinically active while 10 were inactive. The
Table 1 Clinical data of Behc¸et’s disease patients included in
the study.
Behc¸et’s disease patients (N= 30)
Number %
Family history
Positive 2 6.7
Negative 28 93.3
Ocular involvement
Present 12 40
Absent 18 60
Vascular involvement
Present 6 20
Absent 24 80
Pathergy test
Positive 17 56.7
Negative 13 43.3
Oral ulcers
Present 19 63.3
Absent 11 36.7
Genital ulcer
Present 14 46.7
Absent 16 53.3
Cutaneous lesion
Present 14 46.7
Absent 16 53.3
Table 3 Serum TNF-a in relation to clinical data of Behc¸et’s
disease patients included in the study.
TNF-a
mean ± SD
P-value
Ocular involvement
Present 40.6 ± 16.9 0.007*
Absent 24.2 ± 13.8
Vascular involvement
Present 39.5 ± 17.9 0.2
Absent 28.6 ± 16.3
Pathergy test
Positive 30.3 ± 15.3 0.9
Negative 31.1 ± 18.6
Oral ulcer
Present 33.0 ± 18.2 0.3
Absent 26.8 ± 14.6
Genital ulcer
Present 27.4 ± 14.5 0.3
Absent 33.7 ± 18.8
Cutaneous lesion
Acneiform 32.6 ± 15.2 0.07
Erythema Nodosa 44.7 ± 19.7
Negative 25.3 ± 15.2
* Signiﬁcant difference. TNF-a: tumor necrosis factor.
Table 4 Serum level TNF-a in relation to drug history of
Behc¸et’s disease patients included in the study.
Medication TNF-a (pg/ml)
mean ± SD
P-value
Steroid
Receiving (20) 31.6 ± 15.4 0.7
Not receiving (10) 28.5 ± 21.6
Azathioprine
Receiving (16) 37.8 ± 18.4 0.2
Not receiving (14) 28.2 ± 16.1
Colchicine
Receiving (12) 29.4 ± 19.2 0.7
Not receiving (18) 32.1 ± 14.9
TNF-a: tumor necrosis factor.
Serum tumor necrosis factor alpha (TNF-a) level in patients with Behc¸et’s disease 141BDCAF ranged from 1 to 7 with a mean of 3.4 ± 1.42.
Patients were receiving steroids (10–20 mg/day; median
15 mg/day), azathioprine (50–150 mg/day; median 100 mg)
and colchicines (0.5–1.5 mg/day; median 1 mg/day).
Mean serum TNF-a level of patients with Behc¸et’s disease
was 30.75 ± 16.94 pg/ml and the difference was signiﬁcant
when compared with the control group (5.08 ± 3.19 pg/ml;
P< 0.0001). There was a statistically signiﬁcant difference in
serum TNF-a between patients with active and inactive disease
(P< 0.0001). However there was a statistically signiﬁcant
difference in ESR and Hs-CRP only between the active group
and controls (P< 0.0001, P< 0.001, respectively), and not
between active and inactive group (Table 2).
Patients with ocular manifestation had a statistically
signiﬁcant higher level of serum TNF-a than those with no
ocular lesions (P= 0.007) (Table 3). However there was no
statistical signiﬁcant difference between serum TNF-a level
in BD patients with other active clinical manifestations (oral,
genital ulcers, vascular, cutaneous lesions, pathergy test) and
those with no active manifestations (Table 3).
In our study, the level of TNF-a was found to be higher in
group of patients who were on steroids, azathioprine, and inTable 2 Comparison between Behc¸et’s disease cases according to d
Feature
Mean ± SD
Behc¸et’s disease patients
All patients (N= 30) Active (N= 20)
ESR (mm/1st h) 30.83 ± 26.5 35.75 ± 29.26
Hs-CRP (lg/ml) 14.29 ± 10.4 15.15 ± 10.81
TNF-a (pg/ml) 30.75 ± 16.94 36.51 ± 16.36
* Signiﬁcant differences among active, inactive and control groups. ESR:
protein, TNF-a: tumor necrosis factor.those who were not on colchicine but these were not statisti-
cally signiﬁcant (Table 4).
There was a signiﬁcant correlation between BDCAF and
Hs-CRP with P value (R 0.5, 0.005), however TNF-a did
not signiﬁcantly correlate with BDCAF, ESR, Hs-CRP
(Table 5).isease activity and controls as regards laboratory ﬁndings:
Controls (N= 20) P-value
Inactive (N= 10)
21 ± 17.13 6.30 ± 2.56 <0.0001*
12.58 ± 9.83 4.93 ± 3.15 <0.0001*
19.24 ± 11.78 5.08 ± 3.19 <0.001*
erythrocyte sedimentation rate, Hs-CRP: highly sensitive C-reactive
Table 5 Correlation between TNF-a with laboratory data
and disease activity of Behc¸et’s disease patients included in the
study.
TNF-a (pg/ml)
r
P-value
ESR (mm/1st h) 0.001 0.9
Hs-CRP (lg/ml) 0.02 0.9
BDCAF 0.1 0.5
ESR: erythrocyte sedimentation rate, Hs-CRP: highly sensitive C-
reactive protein, TNF-a: tumor necrosis factor. BDCAF: Behc¸et’s
disease current activity form.
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Behc¸et’s disease (BD) is a systemic vasculitis of unknown
etiology. Increasing studies ﬁnd that a sophisticated interlacing
cytokine network is closely implicated in the onset. [14] Hyper-
activity of the neutrophils is a major part of the immunological
abnormalities observed in BD [15]. Activated neutrophils se-
crete some cytokines which prime themselves and also stimulate
Th1 cells. Th1 lymphocytes have amajor role for immunopatho-
genesis for BD. An overproduction of pro-inﬂammatory cyto-
kines from cellular resources appears to be responsible for the
inﬂammatory reaction in BD. T cell produced cytokines, includ-
ing interleukin (IL)-2, TNF-a, interferon (IFN)-c, IL-12 and IL-
18, are elevated and probably contribute to neutrophil and
endothelial cell activation. And also IL-12 and IL-18, which
are mainly, produced by antigen presenting cells (APCs),
regulate the neutrophil function andmay play an important role
in the skewing of immune response [12].
TNF-a is a pleiotropic cytokine produced by a number of
cell types including macrophages and T-cells and has a crucial
role in the pathogenesis of inﬂammation. It may induce expres-
sion of other proinﬂammatory cytokines and adhesion mole-
cules, making it a prime target for speciﬁc immune therapy [16].
In this study, we tried to determine serum TNF-a levels in 30
Egyptian patientswithBehc¸et’s disease, and 20 healthy controls,
and also to assess if there is a difference in serumTNF-a between
clinically active BD patients and those with inactive disease.
Clinical and laboratory observations suggested an impor-
tant role of TNF-mediated process in the pathogenesis of
BD [17]. In our study we found a statistically signiﬁcant differ-
ence in serum TNF-a between Behc¸et’s disease patients and
control group with higher levels in the ﬁrst group. This was
in agreement with the studies of Akdeniz et al. [18] and Oztas,
et al., [19] who detected that there was elevated serum level of
TNF-a in BD patients compared to controls.
In our study we found no signiﬁcant correlation between
serum TNF-a level and ESR, and Hs-CRP, and this was in
accordance with the results of Bozoglu, et al., [20] who con-
cluded that TNF-a was not found to be correlated with either
ESR or CRP (P> 0.05).
TNF-a is also a pro-inﬂammatory cytokine and is involved in
the blood retinal barrier breakdown by opening tight junctions
of retinal vascular endothelial cells and retinal pigmented epi-
thelial (RPE) cells [21]. Santos et al., [22] study showed signiﬁ-
cant positive correlations between elevated serum TNF-a
levels and recurrent episodes of uveitis associated with BD. Thiswas in agreement with our results as we found higher serum
TNF-a level in BD patients with active ocular manifestations
than those without and this was statistically signiﬁcant. These
results were conﬁrmed by Ohno et al., [23] study who concluded
that the administration of inﬂiximab (TNF-a blocker) in pa-
tients with BD with refractory uveoretinitis suppressed the fre-
quency of ocular attacks, and multiple administration was
well tolerated, suggesting that inﬂiximab is effective for this
condition.
Also we found no relation between the serum level TNF-a
and other active clinical manifestations (oral, genital ulcers,
vascular, cutaneous lesions). In agreement Bozoglu et al. [20]
studied 36 BD patients with venous thrombosis (divided into
3 groups: patients with acute, chronic thrombosis and mucocu-
taneous involvement) and 20 healthy controls and found that
serum TNF-a levels of all groups were higher than those of
the healthy controls (P< 0.001). Nevertheless, no signiﬁcant
difference was noted when patient subgroups were compared
to each other. However, the results of Kartal Durmazlar
et al., [24] were in contrary to our ﬁndings as they found that
the serum levels of TNF-a had a strong association with oral
ulcer, genital ulcer, the presence of positive pathergy test,
and vascular lesion. No association was found between
TNF-a levels and erythema nodosum or arthritis.
In our study, we observed increased serum levels of TNF-a
in patients with active BD and it was statistically signiﬁcantly
higher than those with inactive BD, suggesting that this cyto-
kine is related to disease activity. ESR and Hs-CRP were high-
er in the active BD patients compared to the inactive group.
However the difference was not statistically signiﬁcant. This
was in agreement with Evereklioglu et al., [25] study who
found statistical differences between active BD, inactive BD
patients and controls as regards serum TNF-a level which
was higher in active patients (P< 0.0001).
In conclusion, high levels of TNF-a indicate the activation
of immune response in BD. Serum TNF-a seems to be related
to Behc¸et’s disease activity. High levels of TNF-a were present
in patients with active ocular disease, raising the hope of the
efﬁcacy of anti TNF-a agents in the treatment of refractory
ocular involvement.
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